Mochida Pharmaceutical
Basic Information
- Stock Code
- 4534
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- April 1945
- Listing Year
- May 1963
- Official Website
- https://www.mochida.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Kaken Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Kyorin Pharmaceutical, Otsuka Holdings, Asuka Pharma HD
Overview
Mochida Pharmaceutical is a mid-sized pharmaceutical manufacturer founded in 1945, specializing in prescription pharmaceuticals and healthcare products with hyperlipidemia treatments as its mainstay and holding a strong position in the domestic market.
Current Situation
Mochida Pharmaceutical achieved consolidated sales of approximately ¥103 billion and operating profit of approximately ¥12 billion in the fiscal year ended March 2021, maintaining a stable business foundation. It focuses on the development and sales of prescription pharmaceuticals for circulatory system, emergency medicine, obstetrics and gynecology, and dermatology, with market competitiveness from its product lineup centered on hyperlipidemia treatments. It advances business expansion through external collaborations such as co-promotion with Janssen Pharma and actively invests in new drug development. The medical equipment business has been transferred to Mochida Siemens Medical Systems via spin-off, and in the healthcare business, it develops sensitive skin skincare products through Mochida Healthcare. In recent years, it has strengthened R&D at its formulation research lab and drug discovery lab, and provides academic support via the Mochida Memorial Foundation for Medical and Pharmaceutical Sciences. Moving forward, while addressing intensifying competition in prescription pharmaceuticals and responses to the generic drug market, it aims for expansion in advanced medical fields and overseas markets. Additionally, from a sustainability perspective, it focuses on reducing environmental impact and community contributions, aiming for sustainable growth.
Trivia
Interesting Facts
- Founded in 1945, it plays a role in Japan's post-war pharmaceutical industry.
- Product lineup spans circulatory, emergency, OB/GYN, and dermatology.
- Actively engages in co-promotions, collaborating with Janssen Pharma.
- Established Mochida Memorial Foundation for Medical and Pharmaceutical Sciences in 1983 for academic support.
- Fullfull medicated shampoo in healthcare business enjoys enduring popularity.
- Medical equipment business spun off in 2002 to pursue specialization.
- Maintains sales bases nationwide, with strong ties to regional healthcare.
- Mainstay hyperlipidemia treatments widely used in Japanese market.
- Emphasizes scientific basis in dermatology for sensitive skin skincare products.
- Pharmaceutical manufacturing plants maintain high standards in quality control.
Hidden Connections
- Public interest Mochida Memorial Foundation for Medical and Pharmaceutical Sciences makes significant contributions to pharmaceutical research.
- Strengthened sales network through joint promotions with Janssen Pharma.
- Utilizes contract manufacturers for flexible production system.
- Close collaboration with pharmacies, contributing to regional healthcare.
- Realized application of pharmaceutical technology by entering cosmetics market.
- Specific hypertension treatment drug established as staple in medical settings.
- Strong collaboration with dermatology experts and physicians in product development.
- Local pharmaceutical and research facilities contribute to regional economy.
Future Outlook
Growth Drivers
- Increasing demand for prescription pharmaceuticals due to aging population
- Expansion of treatments for lifestyle-related diseases including hyperlipidemia
- Growth in healthcare product market and rising needs for sensitive skin care
- Revenue growth from successful new drug R&D
- Enhanced digital marketing and sales efficiency
- Market share expansion via generic drug market entry
- Utilization of sublicensing and collaborations in medical equipment business
- Maintenance and strengthening of region-focused sales system
- Enhanced corporate value through addressing environmental and social issues
- Stable business foundation via strengthened regulatory compliance domestically and internationally
Strategic Goals
- Achieve over ¥120 billion in annual prescription pharmaceutical sales
- Expand healthcare product sales to ¥30 billion
- Enrich new drug development pipeline and promote launches
- Establish sustainability policy and achieve targets
- Strengthen business expansion in overseas markets
- Expand research grants via Mochida Memorial Foundation for Medical and Pharmaceutical Sciences
- Advanced customer engagement using digital technologies
- Further efficiency and advancement in manufacturing and quality control
- Promotion of corporate activities emphasizing coexistence with local communities
- Establishment of comprehensive risk management system
Business Segments
Pharmaceutical Contract Manufacturing
- Overview
- Provides contract manufacturing services for pharmaceuticals, accommodating diverse formulation technologies.
- Competitiveness
- Advanced formulation technology and quality management system
- Customers
-
- Domestic pharmaceutical companies
- Overseas pharmaceutical companies
- Research institutions
- Biotech ventures
- Products
-
- Pharmaceutical formulation contracting
- API contract manufacturing
- Packaging and labeling
- Quality testing services
Generic Drug Development & Sales
- Overview
- Engages in development and sales of generic drugs, contributing to healthcare cost reduction.
- Competitiveness
- Efficient development system and stable supply capability
- Customers
-
- Hospitals and clinics
- Pharmacies
- Pharmaceutical wholesalers
- Retail pharmacy chains
- Products
-
- Generic pharmaceuticals
- Generic drug development
- Quality management
- Sales support
Healthcare Product Supply
- Overview
- Supplies cosmetics and medicated products for sensitive skin care across a wide range of channels.
- Competitiveness
- Product development based on dermatological science
- Customers
-
- Drugstores
- Supermarkets
- Online retailers
- Beauty salons
- Products
-
- Skincare products
- Medicated shampoo
- Sensitive skin cosmetics
- Moisturizing cream
R&D Support
- Overview
- Provides various services related to drug discovery and pharmaceutical research.
- Competitiveness
- Expertise and know-how from years of pharmaceutical research
- Customers
-
- Universities and research institutions
- Pharmaceutical companies
- Biotechnology companies
- Products
-
- New drug discovery
- Clinical trial support
- Drug discovery research support
Competitive Advantage
Strengths
- Established market position in hyperlipidemia treatments
- Broad product portfolio in prescription pharmaceuticals
- Academic support via Mochida Memorial Foundation for Medical and Pharmaceutical Sciences
- Healthcare product expansion based on dermatology
- Long-term reliability and stable business foundation
- Extensive domestic sales and marketing network
- Collaboration capabilities in co-promotions
- Robust R&D organization
- Advanced quality control and manufacturing technology
- Diverse customer base across sales channels
Competitive Advantages
- Niche expertise as a mid-sized pharma company
- Differentiated pharmaceutical lineup centered on hyperlipidemia treatments
- Penetration in healthcare market with sensitive skin products
- New drug development capabilities backed by abundant R&D resources
- Focused management through spin-off of medical equipment division
- Promotion of pharmaceutical research via public interest foundation
- Comprehensive nationwide sales bases
- Efficient operations commensurate with consolidated sales scale
- Risk diversification across multiple disease areas
- Sales channel expansion via co-promotion initiatives
Threats
- Regulatory tightening in prescription pharmaceutical market
- Intensifying competition in generic drug market
- Rising costs and declining success rates in new drug development
- Demand contraction due to domestic population decline
- Competitive pressure from large multinational pharma companies
- Impact of healthcare cost containment policies
- Profit squeeze from drug price revisions
- Lagging response to rapid technological innovations
- Raw material price fluctuation risks
- Revenue loss risks from patent expirations
Innovations
2023: Advancing development of new hyperlipidemia treatments
- Overview
- Accelerating clinical development of next-generation hyperlipidemia drug candidates while improving safety.
- Impact
- Strengthening market competitiveness with future mainstay products
2022: Strengthening drug discovery lab research
- Overview
- Focus on target exploration in new disease areas and advancement of drug discovery platform technologies.
- Impact
- Diversification and deepening of R&D pipeline
2021: Mochida Healthcare adopts new skincare technology
- Overview
- Introduced dermatologically validated moisturizing technology in new products for sensitive skin.
- Impact
- Product differentiation and improved customer satisfaction
2023: Enhancing digital marketing for prescription pharmaceuticals
- Overview
- Expanding information provision to healthcare professionals using digital tools.
- Impact
- Improved sales promotion efficiency and customer relations
Sustainability
- Improving manufacturing processes to reduce environmental impact
- Promoting social contribution activities for regional healthcare support
- Strengthening systems for product safety and quality assurance
- Enhancing employee health and welfare initiatives
- Sustainable resource utilization and waste reduction